---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004173"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:18:02.208962+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# IO Biotech: Phase 3 melanoma trial continues; Phase 2 lung cancer shows 4 partial responses; $142.7M cash

## Summary
- IDMC recommends Phase 3 melanoma trial continue without changes; enrolling at >80 sites globally.
- Initial Phase 2 basket data: 9 evaluable NSCLC patients: 4 partial responses, 4 stable disease, 1 progressive disease.
- New investigator-initiated study with Johns Hopkins for SCCHN expected H1 2023; total 4 IITs ongoing.
- Preliminary cash $142.7M at Dec 31, 2022; expected to fund operations into mid-2024.

## SEC filing metadata
- accession: 0001193125-23-004173
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312523004173/0001193125-23-004173-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312523004173/d448682d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004173
- JSON: https://secwatch.observer/filing/0001193125-23-004173.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004173.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.